Bbva Compass Bancshares Inc. decreased its stake in shares of Shire PLC (NASDAQ:SHPG) by 11.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,843 shares of the biopharmaceutical company’s stock after selling 247 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Shire PLC were worth $305,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. HPM Partners LLC bought a new position in shares of Shire PLC during the first quarter worth approximately $1,534,000. Vanguard Group Inc. raised its stake in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares in the last quarter. BlackRock Inc. raised its stake in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Laurion Capital Management LP acquired a new stake in shares of Shire PLC during the first quarter worth about $10,611,000. Finally, Atria Investments LLC raised its stake in shares of Shire PLC by 32.6% in the second quarter. Atria Investments LLC now owns 1,648 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 405 shares in the last quarter. Institutional investors and hedge funds own 20.22% of the company’s stock.
Shire PLC (SHPG) traded down 1.62% during midday trading on Friday, hitting $145.55. The stock had a trading volume of 1,456,564 shares. Shire PLC has a 12-month low of $144.18 and a 12-month high of $209.22. The stock has a 50-day moving average price of $160.70 and a 200 day moving average price of $171.91.
The firm also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be issued a dividend of $0.1527 per share. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s payout ratio is 40.63%.
TRADEMARK VIOLATION WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/08/19/bbva-compass-bancshares-inc-has-305000-stake-in-shire-plc-nasdaqshpg-updated.html.
A number of equities research analysts have weighed in on SHPG shares. Cantor Fitzgerald set a $222.00 target price on Shire PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Jefferies Group LLC reaffirmed a “hold” rating and set a $206.00 target price (down from $216.00) on shares of Shire PLC in a research report on Wednesday, August 9th. Barclays PLC downgraded Shire PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $210.00 price target on shares of Shire PLC in a report on Thursday, July 13th. Finally, Evercore ISI started coverage on Shire PLC in a report on Wednesday. They issued an “outperform” rating and a $196.00 price target on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have assigned a buy rating to the stock. Shire PLC has an average rating of “Buy” and a consensus target price of $220.08.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.